|
Market Closed -
OTC Markets
21:31:03 16/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 1.390 USD | 0.00% |
|
0.00% | -46.54% |
| 09-16 | 11 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
| 09-14 | US Regulator Accepts Orexo's New Drug Application for Anaphylaxis Treatment | MT |
| Market Cap | 447M 45.32M 39.52M 37.32M 33.89M 63.49M 4.35B 63.75M 172M 2.21B 170M 166M 7.11B | P/E 2026 * |
-1.22x | P/E 2027 * | -1.76x |
|---|---|---|---|---|---|
| Enterprise Value | 342M 34.68M 30.24M 28.55M 25.93M 48.58M 3.33B 48.78M 132M 1.69B 130M 127M 5.44B | EV / Sales 2026 * |
18x | EV / Sales 2027 * | 16.6x |
| Free-Float |
78.37% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Orexo AB
| Current month | -21.47% | ||
| 1 month | -21.47% | ||
| 3 months | -30.50% | ||
| 6 months | -47.55% | ||
| Current year | -46.54% |
| 1 week | 1.39 |  | 1.39 |
| 1 month | 1.39 | | 1.39 |
| Current year | 1.36 | | 2.65 |
| 1 year | 1.36 | | 4.05 |
| 3 years | 0.89 | | 4.05 |
| 5 years | 0.76 | | 4.05 |
| 10 years | 0.76 | | 9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 54 | 05/02/2013 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 59 | 01/09/2022 |
Jonas Savmarker
CTO | Chief Tech/Sci/R&D Officer | - | 01/10/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 64 | 01/01/2002 | |
George Wilkinson
BRD | Director/Board Member | 70 | 11/04/2019 |
Christine Rankin
BRD | Director/Board Member | 62 | 01/04/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | - | - | 45.67M | |
| -0.19% | +1.49% | +81.01% | +36.60% | 363B | |
| -1.22% | -1.37% | +20.62% | -21.54% | 65.62B | |
| +2.53% | +5.09% | +48.33% | +186.72% | 12.45B | |
| -0.29% | +2.27% | -5.37% | -16.54% | 7.6B | |
| -1.89% | -6.83% | -27.65% | -14.90% | 4.49B | |
| -2.06% | -3.80% | -34.68% | +5.56% | 4.19B | |
| +1.48% | +2.36% | -31.20% | -13.91% | 2.92B | |
| -2.14% | +0.74% | -6.25% | +43.69% | 2.49B | |
| -0.41% | -0.71% | -28.25% | -33.78% | 1.93B | |
| Average | -0.52% | +0.50% | +1.84% | +19.10% | 51.64B | |
| Weighted average by Cap. | -0.57% | +1.38% | +66.47% | +30.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 19M 1.93M 1.68M 1.59M 1.44M 2.7M 185M 2.71M 7.33M 93.98M 7.24M 7.08M 302M | 27M 2.74M 2.39M 2.25M 2.05M 3.83M 263M 3.85M 10.42M 134M 10.28M 10.06M 430M |
| Net income | -375M -38.02M -33.16M -31.31M -28.43M -53.26M -3.65B -53.49M -145M -1.85B -143M -140M -5.97B | - |
| Net Debt | -105M -10.65M -9.28M -8.77M -7.96M -14.91M -1.02B -14.98M -40.52M -519M -39.99M -39.1M -1.67B | - |
Employees
61
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/09/26 | US$1.390 | 0.00% | 100 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ORX Stock
- ORXOY Stock
Select your edition
All financial news and data tailored to specific country editions
